Judith Wessels-Kranz

Title: Judith Wessels-Kranz: Innovator in Antibody Development

Introduction

Judith Wessels-Kranz is a prominent inventor based in Frankfurt am Main, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies for therapeutic applications. With a total of 2 patents, her work focuses on innovative solutions for treating systemic lupus erythematosus (SLE).

Latest Patents

Judith's latest patents include the development of humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE). These patents describe a humanized or chimeric antibody or fragment capable of binding to interleukin-10 (IL-10). The antibodies are designed to be administered to subjects without causing an intolerable increase in pro-inflammatory cytokines. Furthermore, the patents outline methods of treatment that utilize these antibodies or fragments.

Career Highlights

Judith Wessels-Kranz is currently associated with Biotest AG, where she continues to advance her research in antibody development. Her work has been instrumental in paving the way for new therapeutic options for patients suffering from autoimmune diseases.

Collaborations

Judith collaborates with notable colleagues such as Frank Osterroth and Christoph Uherek, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Judith Wessels-Kranz exemplifies the spirit of innovation in biotechnology through her groundbreaking work on humanized antibodies. Her contributions are vital in the ongoing quest for effective treatments for complex diseases like systemic lupus erythematosus.